MIPH Stock Overview
MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.
MINAPHARM Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م236.27|
|52 Week High||ج.م252.00|
|52 Week Low||ج.م128.50|
|1 Month Change||15.83%|
|3 Month Change||18.64%|
|1 Year Change||69.11%|
|3 Year Change||193.50%|
|5 Year Change||179.61%|
|Change since IPO||2,498.97%|
Recent News & Updates
|MIPH||EG Pharmaceuticals||EG Market|
Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned 20.2% over the past year.
Return vs Market: MIPH underperformed the EG Market which returned 71.5% over the past year.
|MIPH Average Weekly Movement||5.3%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||6.5%|
|10% most volatile stocks in EG Market||10.0%|
|10% least volatile stocks in EG Market||4.5%|
Stable Share Price: MIPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MIPH's weekly volatility (5%) has been stable over the past year.
About the Company
|1958||n/a||Wafik El Bardissi||https://www.minapharm.com|
MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Corneregel fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Netophtiole plus eye drops; Extrauma cream; and Ophtatrov and Optatrov plus. It also provides Ferroduonal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, Pixcolt, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.
MINAPHARM Pharmaceuticals Fundamentals Summary
|MIPH fundamental statistics|
Is MIPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MIPH income statement (TTM)|
|Cost of Revenue||ج.م2.40b|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||41.64|
|Net Profit Margin||11.51%|
How did MIPH perform over the long term?See historical performance and comparison